Simulation champions we are so excited to launch our new SIMCharacters.com website! Marketing & Strategy Consultant Lance Baily helped us to migrate our previous website onto a new platform which will enable us to better provide you with information about our company, the World’s first High Emotion Simulator Paul, news updates, and more!
Cytomegalovirus (CMV) infection is the leading cause of congenital infection worldwide, occurring in 1 – 2.5 % of all new-borns in the developed world, conferring risk of deafness, impaired intellectual development, and death
Publication in Clinical and Vaccine Immunology demonstrates that vaccination with Hookipa’s Vaxwave® novel bivalent vaccine expressing human CMV glycoproteins gB & pp65 is protective against congenital guinea pig CMV infection
Mortality rate of 8% for those vaccinated with Hookipa’s HB-101 bivalent Vaxwave® vaccine versus 93% in control group
Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines, today announced that it has signed a research license agreement with MSD Animal Health, known as Merck Animal Health in the United States and Canada.